Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-cataract inflammation: subconjunctival steroid versus topical steroid, with or without physostigmine
NL-OMON24307Phase 4Active, not recruiting
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Jan 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of physostigmine in Postoperative ocular inflammation (4 arms), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoints: Laser flare count and Macular thickness. Started Jan 2007; status: active, not recruiting.
02
Drugs
physostigmine
03
Conditions
Postoperative ocular inflammation
Beyond the preview
Go deeper on NL-OMON24307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24307.